A private equity investment firm based in Israel is investing from a new fund that aims to close at $300M. For early-stage companies, the firm typically invests from few $100K to a couple million per company; for platforms/late stage, the firm usually invest up to $25M per company; and may syndicate for more capital if required. The firm invests in two platform deals and one early-stage company per year. The firm is interested in companies based in the U.S., Europe, or Israel.
The firm is interested in medical devices only. The firm is agnostic to disease indication and is not interested in pharmaceuticals. Accelmed may be interested in the diagnostics and digital health space, though is quite selective in these opportunities. For early-stage opportunities, the firm is interested in disruptive technologies at IP and/or preclinical stage. In the past, the firm has invested in cardiology and diabetes, and is currently looking at neurology; the firm is also open to new areas of focus. For late-stage/Platform companies, the firm is interested in those that have sales between $30-70M as well as sales organization in different fields within the company’s space.
For early stage investment, the firm does not have a management team requirement, as it has the capability to invest in technology and IP alone and build the team around it. The firm is very active post investment by taking more than just a board seat, the firm gets very involved in the company formation and development.
If you are interested in more information about this investor and other investors tracked by LSN, please email email@example.com